Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.

Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willett C; Radiation Therapy Oncology Group Trial 0012.

J Clin Oncol. 2006 Feb 1;24(4):650-5.

PMID:
16446336
2.

Combined-modality therapy of rectal cancer with irinotecan-based regimens.

Minsky BD.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):49-55. Review.

3.

Neoadjuvant chemoradiation for rectal cancer: is more better?

Patel A, Puthillath A, Yang G, Fakih MG.

Oncology (Williston Park). 2008 Jun;22(7):814-26; discussion 826, 828-31, 836. Review.

4.

Integration of novel agents into combined-modality treatment for rectal cancer patients.

Rödel C, Sauer R.

Strahlenther Onkol. 2007 May;183(5):227-35. Review.

PMID:
17497093
5.

Combined-modality therapy for rectal cancer using irinotecan.

Minsky BD.

Oncology (Williston Park). 2002 May;16(5 Suppl 5):35-8. Review.

6.

[A Case of Rectal Cancer Completely Resected after Successful Treatment with Irinotecan plus Cetuximab-Induced Interstitial Pneumonia with Steroid Pulse Therapy].

Miyake M, Takeda T, Haraguchi N, Uemura M, Ikeda M, Miyazaki M, Maeda S, Yamamoto K, Hama N, Nishikawa K, Miyamoto A, Hirao M, Nakamori S, Sekimoto M.

Gan To Kagaku Ryoho. 2015 Nov;42(12):2334-6. Review. Japanese.

PMID:
26805355
7.

Irinotecan and radiosensitization in rectal cancer.

Illum H.

Anticancer Drugs. 2011 Apr;22(4):324-9. doi: 10.1097/CAD.0b013e3283425c14. Review.

PMID:
21160419

Supplemental Content

Support Center